Protagonist Therapeutics Q2 net loss narrows to $30.6 million from $38.5 million
Protagonist Therapeutics reported second-quarter 2024 results with a net loss of $30.6 million, or $0.50 per share, compared with a net loss of $38.5 million, or $0.68 per share, a year earlier. For the six months ended June 30, 2024, the company reported net income of $176.7 million, driven by $255.0 million of the $300.0 million upfront payment from its Takeda collaboration recognized in the first quarter.
Key points
- Q2 2024 license and collaboration revenue was $4.2 million, compared with $0 in Q2 2023.
- Q2 2024 research and development expense was $33.5 million and general and administrative expense was $9.4 million.
- Cash, cash equivalents and marketable securities were $595.4 million as of June 30, 2024, which the company says provides cash runway through end of 2027.
- Topline results from the Phase 3 VERIFY study of rusfertide are expected in Q1 2025.
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.